Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
625 stopped studies mapped to Malignant Urinary System Neoplasm and descendants · 88% state a reason
Over the 625 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02944357 | Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With… | N/A | withdrawn | Oct 25, 2016 | Mayo Clinic | not stated | Not stated |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | Phase 1 | terminated | Sep 12, 2005 | GlaxoSmithKline | not stated | Not stated |
| NCT02138578 | Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal… | N/A | terminated | May 14, 2014 | University of Michigan Rogel Cancer Center | Due to changes in scanning procedure, and infeasible biopsy and baseline imaging, the trial closed… | Enrollment / accrual |
| NCT01492192 | RGD-PET-CT in Cancer Angiogenesis | Phase 2 | terminated | Dec 14, 2011 | Oxford University Hospitals NHS Trust | not stated | Not stated |
| NCT03150836 | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder… | Phase 2 | withdrawn | May 12, 2017 | Terence Friedlander, MD | Co-PI Albert Chang relocating to UCLA. IND will transfer to UCLA. UCSF will not participate. | Other (stated, no rule matched) |
| NCT03007771 | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild… | Phase 1 | withdrawn | Jan 2, 2017 | Washington University School of Medicine | Decision was made to not go forward with the study | Other (stated, no rule matched) |
| NCT01784978 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m…(SUNRISES) | Phase 2 | terminated | Feb 6, 2013 | Associació per a la Recerca Oncologica, Spain | Lack of recruitment | Enrollment / accrual |
| NCT00003520 | Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT00003452 | Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow enrollment | Enrollment / accrual |
| NCT01622660 | Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic… | Phase 2 | terminated | Jun 19, 2012 | Memorial Sloan Kettering Cancer Center | Safety reasons | Safety / toxicity |
| NCT02089802 | Optimizing Pazopanib Exposure in RCC Patients(OPERA) | Phase 2 | terminated | Mar 18, 2014 | Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. | Early termination due to lack of recruitment | Enrollment / accrual |
| NCT00089778 | Vaccine Treatment of Kidney Cancer | Phase 2 | terminated | Aug 13, 2004 | National Cancer Institute (NCI) | fewer tumors than expected expressed FGF-5, led to end of accrual to cohorts A\&B | Enrollment / accrual |
| NCT01598038 | Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal… | N/A | terminated | May 15, 2012 | Centre Francois Baclesse | not stated | Not stated |
| NCT02027649 | Detection of K14 in Bladder Cancer With a Non Invasive Technique | — | terminated | Jan 6, 2014 | Corporacion Parc Tauli | Absence of positive results | Other (stated, no rule matched) |
| NCT02928263 | Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma… | — | withdrawn | Oct 10, 2016 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of… | Phase 1 / Phase 2 | withdrawn | Aug 6, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01042795 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After… | Phase 2 | terminated | Jan 6, 2010 | University of Michigan | Study closed due to poor accrual | Enrollment / accrual |
| NCT02925533 | Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma… | Phase 1 | terminated | Oct 6, 2016 | Mark Pomerantz, MD | Terminated due to safety concerns. | Safety / toxicity |
| NCT01108003 | Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer… | N/A | terminated | Apr 21, 2010 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal…(5-AZ) | Phase 1 / Phase 2 | terminated | Jul 8, 2009 | University of Kansas Medical Center | not stated | Not stated |
| NCT00005047 | 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer | Phase 3 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility… | Safety / toxicity |
| NCT01599832 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib… | N/A | terminated | May 16, 2012 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT00899860 | Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone… | — | terminated | May 12, 2009 | Wake Forest University Health Sciences | PI left institution | Investigator |
| NCT01353222 | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | Phase 2 | terminated | May 13, 2011 | Dendreon | Administrative reasons. | Other (stated, no rule matched) |
| NCT00651482 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001… | Phase 2 | terminated | Apr 2, 2008 | Sandy Srinivas | slow accrual | Enrollment / accrual |
| NCT02071641 | Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Feb 26, 2014 | Amsterdam UMC, location VUmc | not stated | Not stated |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem… | Phase 2 | terminated | Jun 17, 2008 | University of Arizona | Pentostatin/alemtuzumab regimen had greater risk of graft failure. | Other (stated, no rule matched) |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive… | Phase 2 / Phase 3 | terminated | Nov 21, 2011 | Nippon Kayaku Co., Ltd. | Sponsor's decision | Sponsor / business decision |
| NCT00467077 | Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic… | Phase 2 | terminated | Apr 27, 2007 | California Cancer Consortium | Protocol was closed due to slow accrual. | Enrollment / accrual |
| NCT01943188 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With… | Phase 1 | terminated | Sep 16, 2013 | Stanford University | not stated | Not stated |
| NCT01264341 | Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell… | Phase 2 | terminated | Dec 21, 2010 | Hellenic Cooperative Oncology Group | Based on the developments in the treatment of recurrent metastatic renal cancer, the study… | Other (stated, no rule matched) |
| NCT01441765 | PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | Phase 2 | terminated | Sep 28, 2011 | Beth Israel Deaconess Medical Center | Funding | Funding |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | Phase 2 | terminated | Oct 30, 2007 | National Institutes of Health Clinical Center (CC) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT00672178 | Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic,… | Phase 1 / Phase 2 | terminated | May 6, 2008 | Duke University | Slow accrual | Enrollment / accrual |
| NCT01712685 | Imaging Studies of Kidney Cancer Using 18F-VM4-037 | Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | Study was closed to accrual because imaging agent was no longer available. | Enrollment / accrual |
| NCT02410174 | To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma… | Phase 1 | terminated | Apr 7, 2015 | Beth Israel Medical Center | Poor Accural | Other (stated, no rule matched) |
| NCT01410565 | Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle… | Phase 3 | terminated | Aug 5, 2011 | Spectrum Pharmaceuticals, Inc | Business reason | Sponsor / business decision |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and… | Phase 1 | terminated | Nov 29, 2007 | University of Michigan Rogel Cancer Center | closed due to toxicity | Safety / toxicity |
| NCT02252393 | Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder… | N/A | withdrawn | Sep 30, 2014 | Case Comprehensive Cancer Center | waiting on surgeon training | Other (stated, no rule matched) |
| NCT01144169 | Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | Phase 1 | terminated | Jun 15, 2010 | University of Pittsburgh | barriers to accrual: delay until surgery and additional pre-operative visits | Enrollment / accrual |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | Phase 3 | withdrawn | May 23, 2003 | Genentech, Inc. | No patients were enrolled, study cancelled before start | Enrollment / accrual |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT02030574 | Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder… | Phase 2 | terminated | Jan 8, 2014 | Brown University | The study is being closed to accrual secondary to low accrual and an interest in opening up a… | Enrollment / accrual |
| NCT00022633 | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer… | Phase 2 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | Permanently Closed Due to Poor Accrual | Enrollment / accrual |
| NCT00318110 | Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Apr 26, 2006 | Center for International Blood and Marrow Transplant Research | Unable to meet subject enrollment goal. | Enrollment / accrual |
| NCT01336231 | Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in…(COG-ANGIO) | — | terminated | Apr 15, 2011 | Centre Francois Baclesse | lack of recruitment | Enrollment / accrual |
| NCT01326390 | Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular… | — | terminated | Mar 30, 2011 | Stanford University | not stated | Not stated |
| NCT01339000 | Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had… | Phase 2 | terminated | Apr 20, 2011 | National Cancer Institute (NCI) | Company supplying drug declared bankruptcy, thus there was no drug supply. | Drug supply |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy… | Phase 2 | withdrawn | Mar 24, 2016 | Mayo Clinic | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 17, 2017source: clinicaltrials